Stem cell bond issue has narrow lead in poll
By Associated Press,
Associated Press
| 10. 11. 2004
A controversial measure that would provide $3 billion in state bond money to pay for human embryonic stem cell research holds a narrow margin of support among voters, according to a new Field Poll.
Proposition 71, designed to get around the Bush administration's funding limits on such research, would authorize the state to sell bonds to provide annual payments of about $300 million to scientists and companies doing stem cell research.
The poll found that 46 percent of likely voters support the idea with 39 percent opposed and 15 percent undecided. The margin of error was 4.3 percentage points.
The numbers are a slight improvement from an August poll that found 45 percent supported the bond measure to 42 percent opposed.
Supporters of the proposition -- including a coalition of influential Democratic donors and several Silicon Valley tycoons -- have raised more than $12 million for the campaign and are running TV ads.
The Field Poll found that half of those surveyed said they had seen or heard something about the initiative -- an improvement since August of 10 percentage...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...